Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520 by Advanced Tumor Subjects

NCT03657381 is registered in ClinicalTrials.gov with Shandong New Time Pharmaceutical Co., LTD as lead sponsor.

NCT NCT03657381
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03657381 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520 by Advanced Tumor Subjects
Lead sponsor
Shandong New Time Pharmaceutical Co., LTD
Phase
Phase 1
Overall status
Unknown status
Start date
March 1, 2019
Completion date
October 8, 2022
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor，recurrent solid tumor，lymphoma，recurrent lymphocyte depleted classical hodgkin lymphoma